Infliximab
Infliximab is a chimeric humanised mouse anti-TNF monoclonal antibody, that binds to and inhibits human TNF-alpha.
It has been used in the treatment for acute Crohn's disease, but was primarily designed for the treatment of rheumatoid arthritis.
It is given by intravenous infusion at 0,2 and 6 weeks then every 8 weeks thereafter. It is licensed for concomitant use with Methotrexate in adults with RA responding inadequately to DMARDs including methotrexate.
Check the Summary of Product Characteristics before prescribing this drug.
Reference
- NICE. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal guidance TA375. Published January 2016
Related pages
- Dosage of infliximab
- Contraindications to the use of infliximab
- Clinical efficacy of infliximab
- Side effects of infliximab
- Infliximab in Crohn's disease and ulcerative (UC) colitis
- NICE guidance - the use of infliximab or adalimumab in Crohn's disease
- NICE guidance - etanercept , infliximab and adalimumab for the treatment of adults with psoriatic arthritis
- Anti-TNF alpha therapies for rheumatoid arthritis
- Monitoring infliximab
- NICE guidance - infliximab for the treatment for adults with psoriasis
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.